Circio selected to deliver oral presentation at the prestigious ESGCT annual meeting

Summary by AI BETAClose X

Circio Holding ASA announced that its abstract titled 'circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies' has been selected for an oral presentation at the prestigious European Society of Gene and Cell Therapy annual meeting in Hamburg, Germany, from October 27-30, 2026. This selection, alongside two poster presentations, highlights the scientific merit of Circio's proprietary circVec platform, which has demonstrated significant improvements in RNA half-life and protein expression compared to conventional mRNA-based systems, potentially impacting the development of advanced gene and cell therapies.

Disclaimer*

UK 100

Latest directors dealings